The IBEX 35 tracks 35 liquid shares in Spain using free-float-adjusted market-cap weighting. Learn its selection, calculation, and risks.
The IBEX 35 is a real-time index of 35 highly liquid securities traded through the interconnected system of Spain’s four stock exchanges. Selection is led by liquidity and investability rules rather than a simple ranking of Spain’s 35 largest companies. Constituent weights use index-computable shares adjusted by stepped free-float factors, with a 20% constituent cap applied at reviews under the current methodology.
The index is designed to show the real-time performance of the most liquid shares traded on Spain’s electronic equity market and to support products such as index derivatives. It contains 35 securities, but market capitalization alone does not determine membership.
For scheduled reviews, the current technical regulations use a six-month control period. The committee considers euro trading volume and the quality of that trading, including transaction concentration, trading frequency, bid-ask spreads, turnover, suspensions, and whether the index can be replicated efficiently.
An inclusion candidate’s average index-computable capitalization must exceed 0.30% of the index’s average capitalization during the control period. This is a threshold, not a rule that the 35 highest market-cap companies must be selected.
A simplified selection process is:
For a recently listed security, the committee can apply special rules rather than require a complete six-month history. Analysts should check the current methodology and review announcement instead of assuming a new large listing enters immediately.
The simplified computable market capitalization of constituent (i) is:
where (P_i) is the share price, (S_i) is the relevant share count, and (F_i) is the free-float factor. A simplified uncapped weight is:
The methodology does not always use the exact free-float percentage as (F_i). It assigns a stepped factor:
| Reported free-float band | Index factor |
|---|---|
| 10% or less | 10% |
| More than 10% through 20% | 20% |
| More than 20% through 30% | 40% |
| More than 30% through 40% | 60% |
| More than 40% through 50% | 80% |
| More than 50% | 100% |
At ordinary and follow-up reviews, the weight of one constituent is limited to 20%. That limit is applied through the index share count and does not prevent a weight from rising above 20% later as prices change.
Assume three fictional eligible companies before the 20% review cap is applied:
| Company | Full market value | Actual free float | Methodology factor | Computable market cap | Uncapped weight |
|---|---|---|---|---|---|
| A | EUR 100 billion | 25% | 40% | EUR 40 billion | 30.30% |
| B | EUR 80 billion | 55% | 100% | EUR 80 billion | 60.61% |
| C | EUR 60 billion | 15% | 20% | EUR 12 billion | 9.09% |
| Total | EUR 240 billion | EUR 132 billion | 100% |
Company B receives the highest uncapped weight even though Company A has the largest full market value. In the actual 35-security index, packages above the review cap would be reduced and the remaining weights would be rescaled. This three-company example therefore explains free-float bands, not final IBEX 35 weights.
A useful simplified index-level formula is:
The official calculation uses an adjustment component to maintain continuity when constituent changes or qualifying financial transactions alter aggregate capitalization. The economic purpose is similar to a divisor adjustment: a mechanical change in shares or index composition should not be reported as market performance.
The base value was 3,000 at the close on December 29, 1989. That base is only a reference scale. An index move from 10,000 to 10,500 is a 5% increase, not a EUR 500 return on every product linked to the index.
The headline IBEX 35 does not adjust for ordinary dividends. Separate official variants incorporate shareholder distributions.
| Series | Ordinary dividends | Typical analytical use |
|---|---|---|
| IBEX 35 | Excluded from return | Measuring share-price performance |
| IBEX 35 Total Return | Reinvested on a gross basis under index rules | Dividend-inclusive benchmark comparison |
| IBEX 35 Net Return | Reinvested after methodology-specified tax treatment | Net distribution comparison under standardized assumptions |
Suppose the price index rises from 10,000 to 10,300:
If the official total-return index rises 4.2% over the same dates, the 1.2 percentage-point difference reflects the effect of distributions and their index treatment over that period. It is not necessarily an investor’s after-tax dividend return.
The Technical Advisory Committee holds two ordinary review meetings each year and two follow-up meetings in the intervening quarters under the current regulations. Follow-up meetings change constituents only when a significant liquidity change supports redefining the index. Extraordinary meetings can address exceptional events.
Decisions from ordinary and follow-up meetings normally take effect on the trading day after the third Friday of the relevant month. Mergers, takeovers, suspensions, delistings, and other events can also change constituents or computable shares between scheduled reviews.
| Index | Main market scope | Constituents | Selection emphasis |
|---|---|---|---|
| IBEX 35 | Liquid shares traded in Spain | 35 | Liquidity, capitalization threshold, replicability |
| CAC 40 | Large, actively traded Paris shares | 40 | Free-float capitalization and trading activity |
| DAX | Major German-listed companies | 40 | Size, liquidity, and eligibility rules |
| FTSEurofirst 300 | Developed European large companies | 300 | Broad developed-Europe coverage |
IBEX 35 is narrower than a broad European index and can carry larger company or sector concentrations. A national listing benchmark also does not imply that all constituent revenue is generated domestically.
The IBEX 35 is not a complete measure of Spain’s economy. It omits private and smaller companies, weights constituents by investable market value rather than economic output, and includes businesses with international revenue and operations.
This article is educational and does not provide investment, tax, or legal advice or recommend an index product, security, derivative, or allocation.